Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Zhao, Ming ^a   Ma, Jian ^b   Zhu, Hai Yan ^b   Zhang, Xu Hui ^a   Du, Zhi Yan ^a   Xu, Yuan Ji ^a   Yu, Xiao Dan ^a  

^a Beijing Institute of Basic Medical Sciences   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Apigenin; Cdc37; CK2; Hsp90; Multiple myeloma (MM)

Indexed keywords

APIGENIN; CASEIN KINASE II; CELL CYCLE PROTEIN 37; CYCLIN DEPENDENT KINASE 4; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; RAF PROTEIN; RECEPTOR INTERACTING PROTEIN 140; STAT3 PROTEIN; SURVIVIN; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; CDC37 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CHAPERONIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; WESTERN BLOTTING; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APIGENIN; APOPTOSIS; CASEIN KINASE II; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHAPERONINS; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 80052023055     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-104     Document Type: Article

References (47)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004, 351:1860-1873. 10.1056/NEJMra041875, 15509819.
2. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003, 369:1-15. 10.1042/BJ20021469, 1223072, 12396231.
3. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009, 66:1858-1867. 10.1007/s00018-009-9154-y, 19387548.
4. Guerra B, Issinger OG. Protein kinase CK2 in human diseases. Curr Med Chem 2008, 15:1870-1886. 10.2174/092986708785132933, 18691045.
5. Ahmad KA, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2--a key suppressor of apoptosis. Adv Enzyme Regul 2008, 48:179-187. 10.1016/j.advenzreg.2008.04.002, 2593134, 18492491.
6. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G, Di Maira G, Barbon F, Cabrelle A, Zambello R, Adami F, Trentin L, Pinna LA, Semenzato G. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006, 108:1698-1707. 10.1182/blood-2005-11-013672, 16684960.
7. Shao J, Prince T, Hartson SD, Matts RL. Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J Biol Chem 2003, 278:38117-38120. 10.1074/jbc.C300330200, 12930845.
8. Miyata Y, Nishida E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol Cell Biol 2004, 24:4065-4074. 10.1128/MCB.24.9.4065-4074.2004, 387775, 15082798.
9. Gray PJ, Prince T, Cheng J, Stevenson MA, Calderwood SK. Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer 2008, 8:491-495. 10.1038/nrc2420, 2779120, 18511936.
10. Mandal AK, Lee P, Chen JA, Nillegoda N, Heller A, DiStasio S, Oen H, Victor J, Nair DM, Brodsky JL, Caplan AJ. Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation. J Cell Biol 2007, 176:319-328. 10.1083/jcb.200604106, 1857360,1857360, 17242065.
11. Bandhakavi S, McCann RO, Hanna DE, Glover CV. A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases. J Biol Chem 2003, 278:2829-2836. 10.1074/jbc.M206662200, 12435747.
12. Miyata Y, Yahara I. The 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activity. J Biol Chem 1992, 267:7042-7047.
13. Miyata Y. Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. Cell Mol Life Sci 2009, 66:1840-1849. 10.1007/s00018-009-9152-0, 19387550.
14. Gray PJ, Stevenson MA, Calderwood SK. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res 2007, 67:11942-11950. 10.1158/0008-5472.CAN-07-3162, 18089825.
15. Smith JR, Clarke PA, de Billy E, Workman P. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2009, 28:157-169. 10.1038/onc.2008.380, 2635547, 18931700.
16. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol 2007, 30:233-245.
17. Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 2007, 6:1102-1114. 10.4161/cc.6.9.4146, 17457054.
18. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin Cancer Res 2004, 10:3169-3178. 10.1158/1078-0432.CCR-03-0586, 15131058.
19. Chen D, Landis-Piwowar KR, Chen MS, Dou QP. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res 2007, 9:R80. 2246179, 18300387.
20. Way TD, Kao MC, Lin JK. Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. FEBS Lett 2005, 579:145-152. 10.1016/j.febslet.2004.11.061, 15620704.
21. Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI, Min YH. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007, 13:1019-1028. 10.1158/1078-0432.CCR-06-1602, 17289898.
22. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002, 94:504-513.
23. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, Shugar D, Pinna LA. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett 2001, 496:44-48. 10.1016/S0014-5793(01)02404-8, 11343704.
24. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85. 10.1038/332083a0, 3258060.
25. Yi X, Wei W, Wang SY, Du ZY, Xu YJ, Yu XD. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. Biochem Pharmacol 2008, 75:1697-1705. 10.1016/j.bcp.2007.10.035, 18342836.
26. Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA, Bauer S. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 2009, 69:6941-6950. 10.1158/0008-5472.CAN-08-4004, 2905726, 19706776.
27. Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G, Ahmed K. Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol Cancer Ther 2007, 6:1006-1012. 10.1158/1535-7163.MCT-06-0491, 17363494.
28. Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L, Liu ZG. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem 2000, 275:10519-10526. 10.1074/jbc.275.14.10519, 10744744.
29. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007, 14:400-410. 10.1038/sj.cdd.4402085, 17301840.
30. Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell 2009, 138:229-232. 10.1016/j.cell.2009.07.006, 19632174.
31. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 2009, 22:1-6.
32. Lee SH, Ryu JK, Lee KY, Woo SM, Park JK, Yoo JW, Kim YT, Yoon YB. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 2008, 259:39-49. 10.1016/j.canlet.2007.09.015, 17967505.
33. Park J, Kim SH, Kim TS. Inhibition of interleukin-4 production in activated T cells via down-regulation of NF-AT DNA binding activity by apigenin, a flavonoid present in dietary plants. Immunol Lett 2006, 103:108-114. 10.1016/j.imlet.2005.10.002, 16280168.
34. Nicholas C, Batra S, Vargo MA, Voss OH, Gavrilin MA, Wewers MD, Guttridge DC, Grotewold E, Doseff AI. Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol 2007, 179:7121-7127.
35. Kim EK, Kwon KB, Song MY, Han MJ, Lee JH, Lee YR, Lee JH, Ryu DG, Park BH, Park JW. Flavonoids protect against cytokine-induced pancreatic beta-cell damage through suppression of nuclear factor kappaB activation. Pancreas 2007, 35:e1-9.
36. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656. 10.1038/nrc883, 12209154.
37. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002, 100:194-199. 10.1182/blood.V100.1.194, 12070027.
38. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002, 99:1885-1893. 10.1182/blood.V99.6.1885, 11877256.
39. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009, 66:1326-1336. 10.1007/s00018-008-8637-6, 19099185.
40. Vrana JA, Cleaveland ES, Eastman A, Craig RW. Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. Apoptosis 2006, 11:1275-1288. 10.1007/s10495-006-7787-y, 16761109.
41. Wuillème-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005, 19:1248-1252. 10.1038/sj.leu.2403784, 15902294.
42. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004, 23:5301-5315. 10.1038/sj.onc.1207692, 15241487.
43. Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 2004, 3:1259-1262. 10.4161/cc.3.10.1196, 15467463.
44. Kim SH, Ricci MS, El-Deiry WS. Mcl-1: a gateway to TRAIL sensitization. Cancer Res 2008, 68:2062-2064. 10.1158/0008-5472.CAN-07-6278, 18381408.
45. Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95:2630-2636.
46. Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 2004, 104:2886-2892. 10.1182/blood-2004-05-1760, 15217829.
47. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 2005, 19:342-353. 10.1096/fj.04-2175com, 15746177.